Case Reports
doi: 10.1097/00002826-198512000-00002.Sinemet "abusers"
- PMID:4075303
- DOI: 10.1097/00002826-198512000-00002
Item in Clipboard
Case Reports
Sinemet "abusers"
P A Nausieda. Clin Neuropharmacol.1985.
Display options
Format
Display options
Format
Abstract
It is generally assumed that parkinsonian patients perceive their need for antiparkinsonian drugs on the basis of emergent motor symptoms. We describe five patients in whom an apparent psychologic effect from levodopa prompted dosage escalation to the point of toxicity. Abstinence from dopaminergic drugs resulted in the appearance of drug-seeking behavior. Psychologic dependence on levodopa has not previously been reported, but appears to occur in a small subset of parkinsonian patients.
Similar articles
- Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.Cedarbaum JM, Hoey M, Kutt H, McDowell FH.Cedarbaum JM, et al.Clin Neuropharmacol. 1988 Apr;11(2):168-73.Clin Neuropharmacol. 1988.PMID:3378225
- Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, Gilley D.Goetz CG, et al.Neurology. 1988 Jul;38(7):1143-6. doi: 10.1212/wnl.38.7.1143.Neurology. 1988.PMID:3290706Clinical Trial.
- Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.LeWitt PA.LeWitt PA.Neurology. 1992 Jan;42(1 Suppl 1):29-32; discussion 57-60.Neurology. 1992.PMID:1549198Review.
- Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.Hutton JT, et al.Neurology. 1989 Nov;39(11 Suppl 2):67-72; discussion 72-3.Neurology. 1989.PMID:2685652Clinical Trial.
- Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.Fernandez HH, Odin P.Fernandez HH, et al.Curr Med Res Opin. 2011 May;27(5):907-19. doi: 10.1185/03007995.2011.560146. Epub 2011 Feb 25.Curr Med Res Opin. 2011.PMID:21351823Review.
Cited by
- Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ.Giovannoni G, et al.J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):423-8. doi: 10.1136/jnnp.68.4.423.J Neurol Neurosurg Psychiatry. 2000.PMID:10727476Free PMC article.
- Dopamine and addiction: what have we learned from 40 years of research.Solinas M, Belujon P, Fernagut PO, Jaber M, Thiriet N.Solinas M, et al.J Neural Transm (Vienna). 2019 Apr;126(4):481-516. doi: 10.1007/s00702-018-1957-2. Epub 2018 Dec 19.J Neural Transm (Vienna). 2019.PMID:30569209Review.
- Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome.Moum SJ, Price CC, Limotai N, Oyama G, Ward H, Jacobson C, Foote KD, Okun MS.Moum SJ, et al.PLoS One. 2012;7(1):e29768. doi: 10.1371/journal.pone.0029768. Epub 2012 Jan 25.PLoS One. 2012.PMID:22295068Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical